Cargando…

The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer

BACKGROUND: Curcumin is a natural product that is often explored by patients with cancer. Weight loss due to fat and muscle depletion is a hallmark of pancreatic cancer and is associated with worse outcomes. Studies of curcumin's effects on muscularity show conflicting results in animal models....

Descripción completa

Detalles Bibliográficos
Autores principales:	Parsons, Henrique A., Baracos, Vickie E., Hong, David S., Abbruzzese, James, Bruera, Eduardo, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4991455/ https://www.ncbi.nlm.nih.gov/pubmed/26934122 http://dx.doi.org/10.18632/oncotarget.7773

Ejemplares similares

Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service
por: Parsons, Henrique A., et al.
Publicado: (2012)

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
por: Golombick, Terry, et al.
Publicado: (2008)

Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys
por: Tirkey, Naveen, et al.
Publicado: (2005)

Global microRNA expression profiling: Curcumin (diferuloylmethane) alters oxidative stress-responsive microRNAs in human ARPE-19 cells
por: Howell, Jennifer C., et al.
Publicado: (2013)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

An optimized molecular inclusion complex of diferuloylmethane: enhanced physical properties and biological activity
por: Tan, Qunyou, et al.
Publicado: (2012)

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers
por: Liu, Sariah, et al.
Publicado: (2016)

Molecular landscape of pancreatic cancer: implications for current clinical trials
por: Heestand, Gregory M., et al.
Publicado: (2015)

Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation
por: Pratt, V C, et al.
Publicado: (2002)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Computed-Tomography Body Composition Analysis Complements Pre-Operative Nutrition Screening in Colorectal Cancer Patients on an Enhanced Recovery after Surgery Pathway
por: Klassen, Pamela, et al.
Publicado: (2020)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer
por: Palmela, Carolina, et al.
Publicado: (2017)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues
por: Li, Alex M., et al.
Publicado: (2019)

Pitfalls in defining and quantifying cachexia
por: Baracos, Vickie E.
Publicado: (2011)

Psoas as a sentinel muscle for sarcopenia: a flawed premise
por: Baracos, Vickie E.
Publicado: (2017)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Home-based functional walking program for advanced cancer patients receiving palliative care: a case series
por: Lowe, Sonya S, et al.
Publicado: (2013)

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal
por: Janku, Filip, et al.
Publicado: (2013)

High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting
por: Joshi, Rushikesh S., et al.
Publicado: (2022)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
por: Ang, Celina, et al.
Publicado: (2019)

Click chemistry, 3D-printing, and omics: the future of drug development
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Fool’s gold, lost treasures, and the randomized clinical trial
por: Stewart, David J, et al.
Publicado: (2013)

Total Number of Alterations in Liquid Biopsies Is an Independent Predictor of Survival in Patients With Advanced Cancers
por: Vu, Peter, et al.
Publicado: (2020)

Characteristics and survival of patients with advanced cancer and p53 mutations
por: Said, Rabih, et al.
Publicado: (2014)

Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
por: Hong, David S., et al.
Publicado: (2015)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
por: Agashe, Ruchi, et al.
Publicado: (2020)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Muscle and Adipose Wasting despite Disease Control: Unaddressed Side Effects of Palliative Chemotherapy for Pancreatic Cancer
por: Klassen, Pamela N., et al.
Publicado: (2023)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

Altered cancer cell metabolism and cachexia: Calculating the energetic cost of cancer
por: Friesen, Douglas, et al.
Publicado: (2014)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET)
por: Chang, Geraldine H., et al.
Publicado: (2018)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications
por: Cohen, Philip R., et al.
Publicado: (2015)

Cutaneous Metastatic Cancer: Carcinoma Hemorrhagiectoides Presenting as the Shield Sign
por: Cohen, Philip R, et al.
Publicado: (2021)

Nailing the Diagnosis: Onychotillomania in Patients With Artificial Nails—An Underrecognized Phenomenon?
por: Cohen, Philip R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v1n1n81qj3grkmoffvffgi6uds